Tocilizumab Effect on Lipid Profile in Correlation to Cardiovascular Events: A Retrospective Cohort Study

Table 5

Lipoprotein level changes at an indicated time point.

	Tocilizumab		Control
Within group change in lipoprotein levels at 3 months
	Mean differences (SD)		Mean differences (SD)
Total CHOL	0.21 (0.65)	0.09	0.07 (0.5)	0.57
LDL-C (mmol/L)	0.12 (0.64)	0.29	0.21 (0.74)	0.27
	Mean differences;	P	Mean differences; Z
TRIG (mmol/L)	0.05; -1.41	0.16	0.10; -0.48	0.63
HDL-C (mmol/L)	0.13; -2.01	0.04	0.03; -0.99	0.32
Within group change in lipoprotein levels at 6 months
	Mean differences (SD)		Mean differences (SD)
Total CHOL	0.46 (1.13)	0.04	0.35 (0.64)	<0.001
LDL-C (mmol/L)	0.39 (1.11)	0.07	0.30 (0.58)	0.01
	Mean differences;		Mean differences;
TRIG (mmol/L)	0.18; -1.35	0.18	0.14; -1.41	0.16
HDL-C (mmol/L)	0.15; -2.40	0.02	-0.08; -1.49	0.14
Within group change in lipoprotein levels at 12 months
	Mean differences (SD)		Mean differences (SD)
Total CHOL	0.14 (0.81)	0.27	0.35 (0.76)	0.03
LDL-C (mmol/L)	0.11 (0.83)	0.37	0.39 (0.63)	<0.001
	Mean differences;		Mean differences;
TRIG (mmol/L)	0.10; -0.87	0.39	0.12; -1.41	0.16
HDL-C (mmol/L)	0.12; -1.92	0.06	-0.19; -0.27	0.79
Within group change in lipoprotein levels at 18 months
	Mean differences (SD)		Mean differences (SD)
Total CHOL	0.21 (0.67)	0.12	0.58 (0.80)	<0.001
LDL-C (mmol/L)	0.39 (0.53)	<0.001	0.48 (0.72)	<0.001
	Mean differences;		Mean differences;
TRIG (mmol/L)	-0.10; -0.49	0.62	0.09; -1.26	0.21
HDL-C (mmol/L)	-0.01; 0.00	1.00	0.01; -1.03	0.30
Within group change in lipoprotein levels at 24 months
	Mean differences (SD)		Mean differences (SD)
Total CHOL	0.38 (0.83)	0.047	0.36 (0.69)	0.01
LDL-C (mmol/L)	0.33 (0.71)	0.045	0.23 (0.79)	0.15
	Mean differences;		Mean differences;
TRIG (mmol/L)	-0.05; -0.10	0.92	0.18; -0.85	0.40
HDL-C (mmol/L)	0.14; -1.86	0.06	0.01; -0.72	0.47

Wilcoxon signed-rank test conducted; Significant value <0.05.